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Background: Acute Lung Injury (ALI) results into severe inflammation and oxidative stress to the pulmonary tissue. 
Rhamnazin is a natural flavonoid and known for its antioxidant and anti-inflammatory properties.  
Materials and methods: The antioxidative and anti-inflammatory properties rhamnazin were tested for protection against 
the acute lung injury. We investigated whether rhamnazin improves the lipopolysaccharide (LPS)-induced ALI in an animal 
model (rat). We also studied the probable molecular mechanism of action of rhamnazin. Rhamnazin was injected 
intraperitoneally (i.p.) (5, 10 and 20 mg/kg) two days before intratracheal LPS challenge (5mg/kg). The changes in lung 
wet-to-dry weight ratio, LDH activity, pulmonary histopathology, BALF protein concentration, MPO activity, oxidative 
stress, cytokine production were estimated.  
Results: The results showed a significant attenuation of all the inflammatory parameters and a marked improvement in the 
pulmonary histopathology in the animal groups pretreated with rhamnazin. The rhamnazin pretreated group also showed 
activation of Nrf2 pathway and attenuation of ROS such as H2O2, MDA and hydroxyl ion. These results indicated that 
rhamnazin could attenuate the symptoms of ALI in rats due to its strong antioxidant and anti-inflammatory properties.  
Conclusion: The results strongly demonstrated that rhamnazin provides protection against LPS-induced ALI. The 
underlying mechanisms of its anti-inflammatory action may include inhibition of Nrf2 mediated antioxidative pathway. 
 




Acute lung injury (ALI) is a severe form of respiratory failure syndrome. ALI is characterized by pulmonary 
edema, acute respiratory failure and capillary edema (Luh and Chiang, 2007). These symptoms make ALI a life-threatening 
disorder resulting in high mortality in patients (Ware and Matthay, 2000; Frutos-Vivar et al; 2004). The pathogenesis of this 
disease includes acute and chronic inflammation, causing elevated permeability of pulmonary vessels. This increased 
permeability leads to pulmonary edema and infiltration of cells into the alveolar cavities causing the destruction of 
respiration (Piantadosi and Schwartz, 2004). 
ALI may result due to several causes such as aspiration, toxic inhalation, and drowning. ALI may also be caused 
due to several indirect cases such as burns, blood transfusion, sepsis etc. All these causes result in pulmonary inflammation 
which is caused due to the response of vascular tissues towards, the above-stated causes. Gram-negative bacteria have been 
recognized as the main cause of this infection. Lipopolysaccharide (LPS), present in the bacterial cell wall is an important 
virulence factor and is a primary factor known to cause the pulmonary inflammation (Ingenito et al; 2001, Karmpaliotis et 
al; 2002). LPS has been reported to cause ALI through several inflammatory mechanisms (Sanlioglu et al; 2001;Sato et al; 
2002; Suliman et al; 2003). LPS induces a pro-inflammatory tumor necrosis factor (TNF) dependent pathway and causes an 
increased expression of cytokines (Tang et al; 2001; Liu and Lin, 2007). These cytokines include IL-1β, including 
interleukin (IL)-6, and macrophage inflammatory protein 2 (MIP-2), leading to amplification of inflammation signal (Tang 
et al; 2001; Liu and Lin, 2007).  The In addition to activation the generation of cytokines is also induced upon LPS 
exposure. These cytokines include TNF-α and IL-6. These cytokines are known to further activate a feedback loop, thus 
amplifying the pro-inflammatory signal (Ware and Matthay, 2000; Li and Verma, 2002).  
Oxidative stress and inflammation are closely linked and have an important role in the pathogenesis of ALI 
induced by LPS. Oxidative stress causes recruitment of leucocytes and other resident cells leading to inflammation 






(Cachofeiro et al; 2008). Conversely, these cells cause induction of oxidative stress by ROS, nitrogen and chlorine species. 
Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor responsible for induction of genes related to 
antioxidant response elements (Pedruzzi et al; 2012). The activation of Nrf2 is used by the host cells in response to such 
oxidative stresses. Nrf2 is also known to function as a master regulator of the antioxidant response genes (Deramaudt et al; 
2013). 
Flavonoids are a group of natural substances known for their several anti-inflammatory and antioxidative 
properties (Nijveldt et al; 2001). Some flavonoids have previously been indicated for their role in ALI for example, 
Quercetin (Huang et al; 2015) and Naringenin (Fouad et al; 2016). Rhamnazin is a natural flavonoid found in plants such as 
the blackthorn plant. Rhamnazin has been shown to possess strong antioxidant and anti-inflammatory properties (Martini et 
al; 2004). However, no study has yet shown its function in acute lung injury induced by LPS. In the present study, we 
explored, whether rhamnazin can potentially protect against LPS-induced ALI. Additionally, we also elucidated its 
potential molecular mechanism of action. 
 
Materials and methods 
Study animals and design of experiment 
 
Sprague–Dawley rats (adult males, n=60, weighing 250 to 300 g) were provided by the animal house of 
Changzhou jintan district people's hospital. The animals were kept under a 12h by 12h light and dark circadian cycle and 
the under controlled conditions of temperature and humidity. The animals were fed ad libitum, with the standard rat diet 
and water. All the animals’ up-keeping procedures were carried out with approval from the institutional ethical committee 
and in accordance with the Principles of Laboratory Animal Care (NIH publication 85−23, revised in 1985). All efforts 
were made to minimize the number of animals and their suffering. 
Rhamnazin and Escherichia coli LPS were procured from Sigma (USA). The animals were assigned to six groups 
of 10 rats each at random viz. 1) Control (phosphate buffered saline); 2) LPS group (5 mg/kg, administered through 
intratracheal instillation); (3) LPS + vehicle; 4) LPS+Rhamnazin (5 mg/kg) group; (5) LPS+ Rhamnazin (10 mg/kg) group; 
(6) LPS + Rhamnazin (20 mg/kg) group. Saline and Rhamnazin were intra-peritoneally (i.p.) administered 48h before the 
LPS challenge. The rats were euthanized at 24 hours post-LPS administration. The euthanasia was followed by the 
collection of lung samples for subsequent experimental analysis. 
 
Estimation of wet-to-dry weight ratio of the lungs 
 
The extent of pulmonary edema in the experimental groups was assessed by measuring the wet-to-dry weight of 
the lungs (Yang et al; 2005). For this, the left lung was excised immediately, rinsed in phosphate buffer saline (PBS) and 
weighed to determine the lung ‘wet’ weight. The lung was then desiccated for 48 h at 85°C temperature in an oven. The 
lung was again weighted to estimate its ‘dry’ weight. The ratio of the wet-to-dry weight of lung was calculated to quantify 
pulmonary edema. 
 
Lactate dehydrogenase (LDH) assay 
 
The activity of LDH, an enzyme used as a marker for cytotoxicity, was measured as decribed previously (Lee et al; 
2015). LDH activity was measured using LDH estimation kit (Sigma, USA). The supernatants of BALF was added to the 
reagent A (2ml) for 60s and then the reagent B was added. Subsequently, the recording of absorbance was done for 4 m at 
every 60s. The activity of LDH was recorded in U/l. The LDH standards provided by sigma kit were used to ascertain the 
linearity of the curve. 
 
Estimation of the broncho-alveolar lavage (BAL) protein concentration and the cell counts 
 
The protein concentration in BALF was performed as described by Lee et al. (2010). Briefly, Broncho-alveolar 
lavage (BAL) was done by lavaging with 5 ml of PBS and a gentle aspiration. Approximately 90% of the BALF was 
recovered by lavaging. Centrifugation of the BALF was carried out at 1000g for 30 minutes at 4 °C temperature. The 
estimation of total protein in the supernatants was performed by Bradford's method and using the Protein Assay Dye (Bio-
Rad, USA). Protein estimation was performed by generating a standard curve of bovine serum albumin protein (BSA). 
Moreover, estimation of total cell count in the BALF was carried out post re-suspension of the cell pellet in 50 μl PBS. 
 






Estimation of pulmonary Myeloperoxidase (MPO) activity 
 
ALI is characterized by increased neutrophil accumulation in lungs. This elevated neutrophil accumulation can be 
detected by the MPO activity (Kim et al. 2012). For estimation of MPO activity, equal weights of the lung tissues were 
homogenized and centrifuged at 15000g for 30 minutes at 4 °C temperature. The supernatant thus separated was evaluated 
for MPO activity using the MPO ELISA kit (Hycult Biotech, Netherlands) as per the manufacturer's protocol and 
absorbance was measured at 450nm. The absorbance of the samples was measured at 450 nm wavelength. All the 
evaluations were performed in replicates and the units were depicted in per gram.  
 
Measurement of the pulmonary oxidative stress 
 
Oxidative stress parameters were measured as described previously (Trocha et al. 2014). Briefly, the excised lungs 
were homogenized at 10% (w/v) and subsequently centrifuged at 15000g and 4°C temperature for 30 minutes and the 
supernatant thus obtained was used for oxidative stress evaluations using colorimetric methods (spectrophotometer 
MARCEL S350 PRO). The activity of Hydrogen peroxide (H2O2), Malondialdehyde (MDA) and Hydroxyl radical (OH) 
was estimated using the Hydrogen peroxide assay kit (Abcam, USA), lipid peroxidation (MDA) assay kit (Abcam, USA) 
and hydroxyl radical antioxidant capacity assay kit (Eagle, bioscience, USA) respectively.  
 
Examination of pulmonary histopathology 
 
Histopathological examination was performed as described by Li et al. (2016). The upper lobes of the right lungs 
were excised from all the six experimental groups. The lung tissues were fixed in 8% paraformaldehyde for 24 hours, 
dehydrated in ethanol and sliced into 4 µm sections after embedding them in paraffin. Post sectioning, the tissues were 
deparaffinized and subsequently stained using the hemotoxylin-eosin (H&E) stain. Histopathological variations in lungs 




The concentrations of cytokines (IL-6 and TNF-α) in the serum and BALF were estimated using ELISA kit (MN, 
USA), following the manufacturer's protocol. 
 
Western Blot analysis 
 
Antibodies for Nrf2, Trx1, and β-actin were procured from the Abcam Inc. (USA). The concentrations of the 
proteins were estimated as mentioned above. 15 μg of the estimated protein was loaded per well on 12% a sodium dodecyl 
sulfate polyacrylamide (SDS–PAGE) gel. Subsequently, the proteins were electrophoretically transferred on a 
polyvinylidene difluoride (PVDF) membrane after completion of gel run. Blocking of the membranes was performed for 
1.5 hours in Tris-buffered saline which contained 0.2% Tween 20 (TBST) and 2% non-fat dry milk (NFDM). Binding of 
primary antibodies onto the membranes was performed by incubating it with primary antibody solution in TBST and 2% 
NFDM for 8 hours at 4 °C temperature. Then the membrane washing was performed three times with TBST. Subsequently, 
the membranes were incubated with goat anti-mouse secondary antibodies for 2h. Finally, the membranes incubated for 1 
hour with horse radish peroxidase (HRP) conjugated secondary antibodies and developed using an ECL detection system. 
The band density on the membranes was scanned and then analyzed using the ImageJ (NIH, USA) software program. 
 
Isolation of total RNA and qRT-PCR  
 
Total RNA was isolated from macrophages using the RNeasy Mini Kit (Qiagen, USA) subsequently qRT-PCR 
was performed using One-Step qRT-PCR Kit (Qiagen, USA) following the manufacture’s protocol. The designing of qRT-
PCR primers was done using the primer blast (Ye et al. 2012). The melting temperature (Tm) of primers was taken between 
57°C and 63°C. The size of the amplification product was taken between 90 and 120 bp along with a difference in Tm of 
3°C (max). We took three technical replicates for every biological replicate. The quality of RNA was assessed by a 
QIAxpertTM microfluidic UV/VIS spectrophotometer (Qiagen, USA). The PCR master mix included 5 μl DyNAmo Flash 
SYBR Green (Thermo) (2X), 1.5 μl cDNA, 1 μl (5 pm/μl) each primer. The following cycling conditions were used for 
qRT-PCR: denaturation at 95°C for 10 min, 40 denaturation cycles at 95°C for 22 s, annealing with extension at 60°C for 






60 s. The qRT-PCR amplification was performed in ABI 7500 system (Applied Biosystem). The threshold cycle value (Ct) 
for the genes were quantified and normalized by Ct value Glyceraldehyde-3-Phosphate Dehydrogenase (GADPH) 
expression. The relative expression was calculated using the 2−ΔΔCt method (Livak and Schmittgen 2001). The following 
primers were used for qRT-PCR: mouse Nrf2 (5'- CAGAGTGATGGTTGCCCACT-3', 5'- 
CACACACTTTCTGCGTGCTC-3'), Trx1 (5'-AAAGGGTCAAAAGGTGGGGG-3', 5'-
ACAGCTGGTAGCTGGTTACAC-3'); IL-6 (5'-CCAGAATACTTCGAAGTTCC-3', 5'-TATCGGTTAATCCCAAG‑3'), 
TNF‑α, (5'- GATCGGTCCCCAAAGGGATG-3', 5'-CCACTTGGTGGTTTGTGAGTG-3'), MIP-2 (5'-
GCTGTCCCTCAACGGAAGAA-3', 5'-CTCAGACAGCGAGGCACATC-3'), IL-1β (5'-
GCCACCTTTTGACAGTGATGAG-3', 5'-GACAGCCCAGGTCAAAGGTT-3'), GAPDH (5′-
GAGAGAGGCCCAGCTACTCG-3′, 5′-CCTCCCGCCCTGCTTATCC-3′) was taken as an internal control. 
 
Statistical evaluation 
The quantitative results were depicted as means ± SEM. All the quantitative results were statistically analyzed by 
one-way analysis of variance (ANOVA). The analysis for multiple tests correction was performed by Bonferroni's method. 
All the statistical calculations were performed in SPSS software program. The maximum threshold for statistically 
significant P-values was set at 0.05. 
 
Results 
The effect of rhamnazin on pulmonary hyperpermeability and edema  
Exposure to LPS caused a significant increase in the wet-to-dry weight ratio of the lungs (Fig. 1) when compared 
to the control treated and vehicle treated animals. Additionally, the BALF protein concentration also showed a significant 
increase (Fig. 1) in comparison to the control treated and vehicle treated animals. These two parameters were significantly 
reduced in rhamnazin pre-treatment groups in a dose dependant manner. Similarly, the levels of LDH were significantly 
























Figure 1: Effect of rhamnazin pretreatment on (A) lung wet/dry ratio, (B) lung tissue LDH level and (C) protein 
concentration in the bronchoalveolar lavage fluid. Data are presented as the mean ± standard error (n=10). *P<0.05 
compared with the LPS-induced ALI group; #P<0.05 compared with the vehicle-treated ALI group. ALI, acute lung injury; 
LPS, lipopolysaccharide; LDH, lactate dehydrogenase. 
Effect of rhamnazin on the histopathologic variations 
 






Histological examination of the lung tissue was performed 24 hours after LPS induction. As depicted in the Fig. 2, 
the lung tissues of the control treated and vehicle treated animal groups had a normal appearance and were devoid of any 
histopathological changes. It was observed that exposure to LPS treatment exhibited extensive damage to the lung tissue. 
The large-scale intrusion of the inflammatory cells inside the pulmonary interstitium along with migration into the alveolar 
cavities. Moreover, the LPS treatment also resulted into pulmonary edema, hemorrhagia in the stroma, alveolar collapse, 
and alveolar wall thickening. The LPS group that was treated with rhamnazin showed a significant attenuation of the 
histopathological changes especially in the group of animals that were treated with 10 mg and 20 mg/kg of rhamnazin. 
 
 
Figure 2: Effect of rhamnazin pretreatment on pulmonary histopathology. (A) phosphate‑buffered saline‑treated healthy 
control group, (B) LPS‑induced ALI group, (C) vehicle‑treated ALI group and (D) 5 mg/kg rhamnazin pretreated ALI 
group (E) 10 mg/kg rhamnazin pretreated ALI group, and (D) 20 mg/kg rhamnazin pretreated ALI group. 
 
Effect of rhamnazin treatment on production of cytokines 
 
The levels of pro-inflammatory cytokines viz. IL-6, TNF-α, MIP-2, and IL-1β in BALF and serum of different 
experimental groups were measured using ELISA. LPS induction caused a significant increase in the serum levels of these 
cytokines in serum (Fig. 3) as well as BALF (Fig. 4). Pretreatment with rhamnazin had a significant effect on the levels of 
cytokines both in serum and BALF when compared to control treated and vehicle treated animal groups. The rhamnazin 








































Figure 3: Effect of rhamnazin pretreatment on LPS‑induced pro‑inflammatory cytokine secretion in the serum of 

























Figure 4: Effect of rhamnazin on LPS‑induced pro‑inflammatory cytokine secretion in the BALF of differentially treated 
ALI mice. Levels of (A) TNF‑α, (B) IL-6, (C) MIP-2 and (D) IL-1β in the BALF. 
 






Effect of rhamnazin on MPO activity 
 
The MPO activity and neutrophil count was estimated in homogenates of pulmonary tissue. Moreover, the count 
of neutrophils in BALF was also estimated in the different experimental groups. Induction with LPS caused a significant 
increase in the activity of MPO (Fig. 5). Similarly, the neutrophil count also showed a significant increase in the BALF of 
LPS induced animals. Upon pretreatment with rhamnazin, the increased activity of MPO as well as increased neutrophil 
number showed a significant decrease in comparison to control treated and vehicle treated animal groups in a dose 

























Figure 5: Effect of rhamnazin pretreatment on MPO (myeloperoxidase) activity and neutrophil accumulation in lung 
tissues. (A) MPO activity in the lung tissue homogenates of differentially treated ALI mice. (B) Neutrophil count in the 
lung bronchoalveolar lavage fluid of differentially treated ALI mice. Data are presented as the mean ± standard error 
(n=10). *P<0.05 compared with the LPS-induced ALI group; #P<0.05 compared with the vehicle-treated ALI mice. 
 
Effects of rhamnazin on oxidative stress levels of ALI animals 
 
The levels of oxidative stress in LPS induced ALI rats was estimated by determining the concentration of MDA, 
H2O2 and hydroxyl ion in the experimental groups in vivo. The induction of ALI caused a significant increase in the levels 
of MDA, H2O2 and hydroxyl ion. Upon treatment with rhamnazin at different concentrations, a significant decrease in the 
levels of oxidative stress was observed in the 10mg/kg and 20mg/kg treatment groups (Fig. 6). These results showed that 
rhamnazin has can potentially attenuate the oxidative stress levels in ALI animals induced with LPS. However, the 5mg/kg 
group showed no significant attenuation of oxidative stress. 







Figure 6: Effect of rhamnazin pretreatment on oxidative stress. The levels of (A) H2O2, (B) hydroxyl ion and (C) MDA in 
the homogenized lung tissue. Data are presented as the mean ± standard error (n=10). *P<0.05 compared with the LPS-
induced ALI group; #P<0.05 compared with the vehicle-treated ALI group. MDA, malondialdehyde. 
 
Effects of rhamnazin treatment on the levels of Nrf1 and Trx1 
 
To estimate the antioxidant response of pulmonary cells, the levels of Nrf1 and Trx1 were estimated using qRT-
PCR and western blot analysis. qRT-PCR results showed that as compared to control group, LPS induced ALI animals had 
a significantly decreased expression of Nrf1 and Trx1 mRNA (Fig. 7). Whereas, the pretreatment with rhamnazin caused a 
significant increase in the levels of mRNA of Nrf1 and Trx1. The results of western blot analysis also showed a similar 
trend as that of mRNA expression levels (Fig. 8). In western blot, the protein expression levels of Nrf1 and Trx1 were 
significantly reduced in ALI animals as compared to the control treated and vehicle treated groups. Whereas, the rhamnazin 
































Figure 7: Effect of rhamnazin pretreatment on Nrf2 and Trx1 expression in lung tissues. The mRNA expression levels of 
(A) Nrf2 and (B) Trx1 are shown. Data are presented as the mean ± standard error (n=10). *P<0.05 compared with the 
LPS-induced ALI group; #P<0.05 compared with the vehicle-treated ALI group. Nrf2, nuclear factor erythroid-2-related 























Figure 8: Effect of rhamnazin pretreatment on Nrf2 and Trx1 expression in lung tissues. The protein expression levels were 
determined as (A) western blot analysis (B) Densitometry of western blot was performed to estimate the relative protein 
concentration. Data are presented as the mean ± standard error (n=10). *P<0.05 compared with the LPS-induced ALI 
group; #P<0.05 compared with the vehicle-treated ALI group. Nrf2, nuclear factor erythroid-2-related factor 2; Trx1, 
thioredoxin isoform 1. 
 








In the present study, we identified the anti-inflammatory and antioxidative effects of rhamnazin on the LPS-
induced ALI in rats. This study also attempts to determine the potential mechanism of action of rhamnazin on pulmonary 
inflammation. This is the first such study on rhamnazin, a natural flavonoid found in several plants. Results showed a 
significant attenuation of lung inflammation which was evident from parameters such as decreased wet-to-dry weight ratio 
of the lungs, the concentration of BALF protein, the activity of MPO, cytokine production and migration of inflammatory 
cells. Moreover, the expression of Nrf2 and Trx1 were also found to be significantly increased. Moreover, in all the 
treatment groups a significantly large decrease in the levels of H2O2, MDA and hydroxyl ion was observed. 
The pathology of ALI in humans has strong similarities with the progression of LPS induced ALI in mouse model 
(Rojas et al; 2005). Thus, several researchers have found this model to be the most appropriate for the study of therapeutic 
agents. It has been shown that in LPS induced ALI, there is a significant increase in the levels of inflammatory cytokines, 
proteins, neutrophils in serum and BALF (Jerala, 2007; Lu et al; 2008). The widespread destruction of alveolar spaces, 
edema and infiltration of neutrophils in the alveolar cavities are also the hallmarks of ALI (Ware and Matthay, 
2000;Piantadosi and Schwartz, 2004; Matthay and Zemans, 2011). Increase in the wet-to-dry weight ratio of the lungs 
(Jacob et al; 2008) and an elevated BALF protein concentration due to protein extravasation (Muller-Redetzky et al; 2014) 
are strong indicators of pulmonary inflammation and edema. Both of these parameters were significantly increased upon 
LPS-induction and there was a subsequent significant decrease after rhamnazin treatment. These results indicated 
attenuation of pulmonary edema and vascular leakage in LPS-challenged rats after rhamnazin treatment. 
Pulmonary edema indicated by the wet-to-dry ratio of lungs as well as the BALF protein concentration was further 
confirmed by the observations in lung histology. We observed several inflammatory changes in our rat ALI-model for 
example, pulmonary edema, thickening of pulmonary epithelium and migration of the inflammatory cells into the 
pulmonary interstitial spaces. A marked improvement in the histopathology of lungs was noticed when the LPS-induced 
rats were treated with rhamnazin. This observation provided a direct proof of the effectiveness of rhamnazin in the LPS-
induced ALI, apart from the various measured parameters. 
Uncontrolled and sustained lung inflammation is known to play an important role in the pathogenesis of ALI 
(Goodman et al; 2003; Manicone, 2009). Therefore, a strategy for attenuation of ALI progression should preferably involve 
suppression of immune system mediated inflammation. In the present study we found that rhamnazin exerts a strong anti-
inflammatory response in LPS induced ALI. The levels of inflammatory cytokines were significantly reduced in the serum 
ad BALF of rhamnazin treated group as compared to untreated group. These results provide a strong indication that 
rhamnazin caused attenuation of LPS induced ALI by inhibition of inflammatory cytokines. 
Neutrophil infiltration into lungs is one of the hallmarks of ALI (Lucas et al; 2009; Matthay and Zemans, 2011). 
After LPS-induction, neutrophils migrate across the pulmonary endothelium and epithelium and reach the alveolar spaces. 
Here, the activated neutrophils cause an elevated production of ROS, the release of MPO, cytotoxic and pro-inflammatory 
mediators and increase in micro-vascular permeability (Chignard and Balloy, 2000; Grommes and Soehnlein, 2011). 
Therefore, the persistent presence of neutrophils in the pulmonary cavity is a strong indicator of ALI. In this study, upon 
rhamnazin treatment, the total cell count in BALF as well as that of neutrophils and macrophages was significantly 
decreased. Neutrophils and alveolar macrophages are known to release MPO during acute inflammation of the lungs 
(Chagnon et al; 2015). Increased activity of MPO is a strong indicator of neutrophil migration into the pulmonary 
parenchyma and the alveolar cavities (Reumaux et al; 2003). MPO concentration has been used for estimation of LPS-
induced ALI in many studies, for example,Rittirsch et al. (2008), Tsai et al. (2014). In the rhamnazin pretreated rats, a 
marked reduction in the activity of MPO was observed. This further confirmed a reduced neutrophil infiltration and 
diminished inflammation of lungs. 
ROS are produced by activated cytokines (Tasoulis et al; 2009). ROS can cause several damages to lung tissue 
such as DNA damage, protein oxidation, and lipid peroxidation. In addition to being an anti-inflammatory agent, rhamnazin 
is also known to possess antioxidant properties (Martini et al; 2004). We observed heightened levels of molecules such as 
MDS, H2O2 and hydroxyl ion in the LPS-induced ALI in our results. These levels were significantly normalized with 
rhamnazin pre-treatment, further suggesting the efficacy of rhamnazin in the treatment of ALI. Nrf2 is a well known 
regulator of cellular antioxidant response (Wang et al; 2012). Additionally, the protein Trx1 functions as a redox protein 
against conditions of oxidative stress (Furukawa et al; 2011). In this study, we found that the levels of Nrf2 and Trx1 were 
significantly deactivated in LPS induced ALI animals. However, a significant up-regulation of Nrf2 and Trx1 with 
rhamnazin pretreatment further supported its strong antioxidant properties.  
In this study, plant flavonoid, rhamnazin showed protective properties against LPS-induced ALI. All the 
parameters for measuring pulmonary inflammation showed a significant improvement over the LPS lung. These protective 






properties may be partly due to the inhibition of inflammatory cytokines production. Moreover, rhamnazin may also 
function by its strong antioxidant properties. The strong antioxidant properties of rhamnazin are associated with its ability 
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